Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Rating of "Buy" from AnalystsMarket Beat·Aug 25 at 03:14 AMCLYM-5.77%BLK-0.76%
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy OutlookTip Ranks·Aug 19 at 04:45 AMCLYM-5.77%
Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story?Simplywall·Aug 18 at 06:39 AMCLYM-5.77%
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYMMarket Beat·Aug 16 at 02:29 AMCLYM-5.77%
Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trialPUBT·Aug 14 at 07:33 AMCLYM-5.77%
Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026PUBT·Aug 6 at 06:36 AMCLYM-5.77%
Beyond the Algorithm: What 10 Fringe Stocks Tell Us About the MarketGlobal Report·Jul 28 at 04:13 AMGSUN+7.41%PSX+1.05%
Climb Bio (NASDAQ:CLYM) Trading 10.9% Higher After Analyst UpgradeMarket Beat·Jul 27 at 09:20 AMCLYM-5.77%
